$MRNA

Moderna's mFlusiva, the first mRNA-based flu vaccine, is now available in the U.S. for people 50 and older. According to the company, it was 27% more effective than standard vaccines in clinical trials. The FDA approved it for ages 50-64 via the standard process and for 65+ via an accelerated process. Side effects were mostly mild and temporary.

PwC's Glenn Hunzinger discusses the potential of personalized mRNA cancer vaccines, citing Merck & Co. and Moderna's Phase 3 trial results. He highlights the need for new infrastructure and business models, as well as reimbursement innovations. The success of these vaccines could extend beyond oncology to other diseases, driving investment and industry transformation. PwC partners with AWS and Microsoft for healthcare innovations.

Merck and Moderna's mRNA cancer vaccine, intismeran autogene, showed positive results in a late-stage trial, extending survival time without cancer recurrence or spread. The vaccine, tested on melanoma patients, trains the immune system to target cancer cells. Full results will be presented at the 2026 European Society for Medical Oncology meeting. The trial involved 1,137 participants, with two-thirds receiving the vaccine alongside Keytruda, a standard immunotherapy.

Moderna (MRNA) stock rose 7% on September 24, closing at $195, ahead of key melanoma data to be presented at ESMO on October 24. Analysts are split, with a mean target of $120, 39% below the current price. CEO Stéphane Bancel reframed Moderna as an mRNA platform company, not just a COVID-19 vaccine maker.

Moderna (MRNA) shares rose 0.087% to $194.99 in after-hours trading, following a 6.98% gain during the regular session. The company announced that three abstracts on its investigational therapy, including a Phase 3 trial with Merck & Co.'s (MRK) pembrolizumab, were accepted for presentation at the European Society for Medical Oncology Congress 2026. MRNA has a market cap of $77.78 billion and a 52-week high of $195.71.

Moderna Inc. (MRNA) shares rose 6.98% to $194.82 after high-level talks with the UAE on investment opportunities. The company also awaits trial data for its melanoma treatment, with a large market potential. Hedge funds increased holdings by 10% to $1.5B in Q2.

Moderna (MRNA) shares rose 6.9% today, driven by investor enthusiasm for its cancer vaccine program after positive Phase 3 melanoma results were disclosed in August. The company plans to present data at a medical meeting and share it with regulators. Recent conference appearances have also highlighted its oncology pipeline and broader mRNA platform. Analysts have set various price targets for the stock, with a median of $46.5.

Four biotech stocks reached 52-week highs on September 23, 2026. Alpha Teknova (TKNO) hit $9.35, reporting Q2 revenue of $12.2M. Moderna (MRNA) reached $192.31 after positive clinical trial data. AtriCure (ATRC) hit $65.48 with Q2 revenue of $153.6M. Illumina (ILMN) climbed to $256.17, reporting Q2 revenue of $1.59B.

Moderna's stock (MRNA) rose 43% in June, driven by its focus on mRNA pipeline for cancer, autoimmune diseases, and AI-powered research. The company outlined future plans at its Science Day event, including programs like mRNA-4194 for cancer prevention and mRNA-6007 for autoimmune diseases. Moderna's flu vaccine candidate, mRNA-1010, received a positive FDA advisory committee vote. The stock has gained 144% over the past year.

Meta (META) rose 1% after unveiling new VR glasses and AI devices at its Connect event. Moderna (MRNA) hit a 52-week high but closed down 0.25% as CEO emphasized its mRNA platform focus. Okta (OKTA) jumped 4% on AI optimism. META reached $763.90, MRNA $192.31.